Although the role of EGFR in altering tumor chemosensitivity has not yet been fully elucidated, preclinical studies have suggested that blockade of EGFR, and the resulting reversal of chemoresistance in many tumor types is a viable strategy for treatment of cancers where frontline therapies have failed to induce a cure. The gene discussed is EGFR; the disease is neoplasm.